The Pop in your Job: What drives you / what is your passion:

What drives me is the desire to give back to my community and be an example that Science, Technology, Engineering and Mathematics (STEM) is a true reality and option for troubled inner-city youth as I once was. It’s amazing to work with the world’s most forward-thinking Pharma & Biotech Companies that have broken through the next-level of advanced medicine, technology, genetic engineering and cures to diseases in the 21^st Century! It’s absolutely breath-taking to know that the therapeutics that Lonza helps its customers develop, manufacture and disposition to the world is changing the lives of patients like never before!

CV:

Hello – my name is Anthony Colenburg, Sr and I am the Quality Compliance & Operations Manager at Lonza in the 20K Operations Asset. I am currently responsible for QA On The Floor, batch/lot review and product disposition. I have worked in the Pharma/Biotech Industry for over 13 years through various increasing Quality roles and responsibilities. My long-term goal is to become a Global Quality Leader of a forward-thinking Organization where the culture thrives on its people longing to continuously raise the bar of Quality!

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). Adicet Bio was founded in late 2015 with significant investment from OrbiMed, Novartis Venture Funds and Pontifax. In August 2016, Regeneron and Adicet Bio announced a strategic collaboration to discover and develop next-generation engineered immune-cell therapeutics and in September 2016, Adicet Bio was recognized and named by FierceBiotech as a “Fierce 15” Biotech Company of 2016.